Professor Tian-Lu Cheng

Tel：+886-7-3121101 ext 2697

Email：tlcheng@kmu.edu.twortlcheng5024@gmail.com

Education：

　　Graduate Institute of Life Sciences, National Defense Medical School & Academia Sinica

Courses Offered：

　　Bio-Medical Journal reading and discussion (I)、(II)
　　Entrepreneurial Management：How to Start up a New Company
　　Entrepreneurial Practice

Specialty：

　　Antibody engineering, Gene therapy, Tumor immunology, Functional genomics.

Publications：

1.   Wang YT,Cheng TL*. Computational modeling of cyclic peptide inhibitor-MDM2/MDMX binding through global docking and Gaussian accelerated molecular dynamics simulations, J Biomol Struct Dyn. 2021 Jul;39(11):4005-4014. 2020 SCIIF=3.310 (SCI, 125/299=41.8%) in BIOCHEMISTRY & MOLECULAR BIOLOGY.

2.   Chang TK, Yin TC, Su WC, Tsai HL, Huang CW, Chen YC, Li CC, Chen PJ, Ma CJ, Chuang KH, Cheng TL, Wang JY. Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab Oncol Res. 2021 May 24.doi: 102.3727/096504021X16218531628569. 2020 SCIIF=5.574 (SCI, 76/242=31.4%) in ONCOLOGY.

3.  Lin WW, Cheng YA, Li CC, Ho KW, Chen HJ, Chen IU, Huang BC, Liu HJ, Lu YC, Cheng CM, Huang MY, Lai HW, Cheng TL*. Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy. Sci Rep. 2021 Apr 7;11(1):7598. 2020 SCIIF=4.379 (SCI, 17/73=23.2%) in MULTIDISCIPLINARY SCIENCES.

4.    Hong ST, Su YC, Wang YJ, Cheng TL*, Wang YT*.Anti-TNF Alpha Antibody Humira with pH-dependent Binding Characteristics: A constant-pH Molecular Dynamics, Gaussian Accelerated Molecular Dynamics, and In Vitro Study. Biomolecules. 2021 Feb 23;11(2):334. 2020 IF=4.879 (96/298=32.2%)in BIOCHEMISTRY & MOLECULAR BIOLOGY.

5.    Ho KW, Chen IU, Cheng YA, Liao TY, Liu ES, Chen HJ, Lu YC, Su YC, Roffler SR, Huang BC, Liu HJ, Huang MY, Chen CY, Cheng TL*. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity. J Nanobiotechnology 2021 Jan 9;19(1):16. 2020 SCIIF=10.435 (SCI, 8/159=5%) in BIOTECHNOLOGY & APPLIED MICROBIOLOGY.

6.   Cheng YA, Wu TH, Wang YM, Cheng TL, Chen IJ, Lu YC, Chuang KH, Wang CK, Chen CY, Lin RA, Chen HJ, Liao TY, Liu ES, Chen FM. Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer. J Nanobiotechnology; 2020 Aug 27;18(1):118. 2020 SCIIF=10.435 (SCI, 8/159=5%) in BIOTECHNOLOGY & APPLIED MICROBIOLOGY.

7.   Chen YC, Miao ZF, Yip KL, Cheng YA, Liu CJ, Li LH, Lin CY, Wang JW, Wu DC, Cheng TL*, Wang JY*. Gut Fecal Microbiota Transplant in a Mouse Model of Orthotopic Rectal Cancer. Front Oncol. 2020 Oct 28;10:568012. 2020 SCIIF=6.244 (SCI, 62/242=25.6%) in ONCOLOGY.

8.   Lin CH, Chou HJ, Chang CC, Chen IS, Chang HS, Cheng TL, Kuo YH, Ko HH. Chemical Constituent of β-Glucuronidase Inhibitors from the Root of Neolitsea acuminatissima. Molecules; 2020 Nov 6;25(21):5170. 2020 SCIIF=4.411 (SCI, 116/298=38.9%) in BIOCHEMISTRY & MOLECULAR BIOLOGY.

9.    Lin WW, Wang YJ, Ko CW, Cheng TL*, Wang YT. Cyclic Peptide Inhibitors of the Tsg101 UEV Protein Interactions Refined through Global Docking and Gaussian Accelerated Molecular Dynamics Simulations. Polymers (Basel), 2020 Sep 28;12(10):2235. 2020 SCIIF=4.329 (SCI, 18/88=20.4%) in POLYMER SCIENCE.

10.  Wang YT,Cheng TL*. Computational modeling of cyclic peptide inhibitor-MDM2/MDMX binding through global docking and Gaussian accelerated molecular dynamics simulations. J Biomol Struct Dyn. 2020 Jun 8:1-10.2020 SCI IF= 3.310 (SCI, 125/299=41.8%) in BIOCHEMISTRY & MOLECULAR BIOLOGY.

11.  Chen E, Chen BM, Su YC, Chang YC, Cheng TL, Barenholz Y, Roffler SR. Premature Drug Release from Polyethylene Glycol (PEG)-Coated Liposomal Doxorubicin via Formation of the Membrane Attack Complex.ACS Nano. 2020 Jul 28;14(7):7808-7822. 2020 SCI IF=15.881 (SCI, 11/107=10.2%) in NANOSCIENCE & NANOTECHNOLOGY.

12.  Lin WW, Lu YC, Chuang CH, Cheng TL*. Ab locks for improving the selectivity and safety of antibody drugs.J Biomed Sci. 2020 Jun 25;27(1):76.. 2020 SCI IF= 8.410 (38/195=19.4%)in CELL BIOLOGY.

13.  Chen IJ, Cheng YA, Ho KW, Lin WW, Cheng KW, Lu YC, Hsieh YC, Huang CC, Chuang CH, Chen FM, Su YC, Roffler SR, Cheng TL. *; Bispecific Antibody (HER2 × mPEG) Enhances Anti-Cancer Effects by Precise Targeting and Accumulation of mPEGylated Liposomes. Acta Biomater. 2020 Jul 15;111:386-397. 2020 SCI IF=8.947 (SCI, 10/90=11.1%)in ENGINEERING BIOMEDICAL.

14.  Chang TC, Chen BM, Lin WW, Yu PH, Chiu YW, Chen YT, Wu JY, Cheng TL, Hwang DY, Roffler AS.  Both IgM and IgG Antibodies Against Polyethylene Glycol Can Alter the Biological Activity of Methoxy Polyethylene Glycol-Epoetin Beta in Mice.Pharmaceutics. 2019 Dec 21;12(1). pii: E15. doi: 10.3390/pharmaceutics12010015.2020 SCI IF:6.321 (SCI, 28/275=10.1%) in PHARMACOLOGY & PHARMACY.

15.  Cheng YA, Chen IJ, Su YC, Cheng KW, Lu YC, Lin WW, Hsieh YC, Kao CH, Chen FM, Roffler SR*, Cheng TL*; Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer.Biomater Sci. 2019 Aug 1;7(8):3404-3417. 2020 IF=6.843 (8/40=20%) in MATERIALS SCIENCE, BIOMATERIALS.

16.  Lu YC, Chuang CH, Chuang KH, Chen IJ, Huang BC, Lee WH, Wang HE, Li JJ, Cheng YA, Cheng KW, Wang JY, Hsieh YC, Lin WW*, Cheng TL*;.Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy.PLoS Biol. 2019 Jun 13;17(6):e3000286.2020 IF=8.029 (6/93=6.45%) in BIOLOGY..

17.  Cheng KW, Tseng CH, Tzeng CC, Leu YL, Cheng TC, Wang JY, Chang JM, Lu YC, Cheng CM, Chen IJ, Cheng YA, Chen YL*, Cheng TL*.Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo. Pharmacol Res. 2019 Jan;139:41-49. 2020 IF=7.658 (15/275=5.4%) inPHARMACOLOGY & PHARMACY.

18.  Huang CC, Cheng KW, Hsieh YC, Lin WW, Cheng CM, Yuan SF, Chen IJ, Cheng YA, Lu YC, Huang BC, Tung YC, Cheng TL*.Use of syngeneic cells expressing membrane-bound GM-CSF as an adjuvant to induce antibodies against native multi-pass transmembrane protein. Sci Rep. 2019 Jul 9;9(1):9931. doi: 10.1038/s41598-019-45160-9. 2020 SCIIF=4.379 (SCI, 17/73=23.2%) in MULTIDISCIPLINARY SCIENCES.

19.  Lee CJ, Wang CC, Chen M, Chuang KH, Cheng TL, Jian TY, Wang YM, Huang TH, Liao KW, Tzou SC. Development of an inflammatory tissue-selective chimeric TNF receptor.Cytokine. 2019 Jan;113:340-346. 2020 SCI IF=3.861 (SCI, 91/162=56.1%) in IMMUNOLOGY.

20.  Chen YJ, Chen M, Cheng TL, Roffler SR, Lin SY, Hsu HL, Wang CH, Chen CY, Kao AP, Cheng JJ, Chuang KH. Simply Mixing Poly Protein G with Detection Antibodies Enhances the Detection Limit and Sensitivity of Immunoassays. Anal Chem. 2019 Jul 2;91(13):8310-8317. 2020 SCI IF=6.986 (SCI, 8/83=9.6%) in CHEMISTRY, ANALYTICAL.

21.  Luo CW, Hsiao IL, Wang JY, Wu CC, Hung WC, Lin YH, Chen TY, Hsu YC, Cheng TL, Pan MR..Cell Motility Facilitated by Mono(2-ethylhexyl) Phthalate via Activation of the AKT-β-Catenin-IL-8 Axis in Colorectal Cancer. J Agric Food Chem. 2018 Sep 19;66(37):9635-9644. 2020 SCI IF=5.279 (SCI, 5/58=5.8%) in AGRICULTURE, MULTIDISCIPLINARY.

22.  Hsieh YC, Wang HE, Lin WW, Roffler SR, Cheng TC, Su YC, Li JJ, Chen CC, Huang CH, Chen BM, Wang JY, Cheng TL*, Chen FM*. Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes. Theranostics. 2018 May 9;8(11):3164-3175. 2020 SCI IF=11.556 (SCI, 9/140=6.4%) in MEDICINE, RESEARCH & EXPERIMENTAL.

23. Chuang CH, Chiou SJ, Cheng TL, Wang YT. A molecular dynamics simulation study decodes the Zika virus NS5 methyltransferase bound to SAH and RNA analogue.Sci Rep. 2018 Apr 20;8(1):6336. 2020 SCIIF=4.379 (SCI, 17/73=23.2%) in MULTIDISCIPLINARY SCIENCES.

24.  Chang CJ, Chen CH, Chen BM, Su YC, Chen YT, Hershfield MS, Lee MM, Cheng TL, Chen YT, Roffler SR, Wu JY.A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol. Nat Commun. 2017 Sep 12;8(1):522. 2020 SCIIF=14.919(SCI, 4/73=5.4%)in MULTIDISCIPLINARY SCIENCES.

25.  Chen IJ, Chuang CH, Hsieh YC, Lu YC, Lin WW, Huang CC, Cheng TC, Cheng YA, Cheng KW, Wang YT, Chen FM, Cheng TL*, Tzou SC. Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains. Sci Rep. 2017 Sep 14;7(1):11587. 2020 SCIIF=4.379 (SCI, 17/73=23.2%) in MULTIDISCIPLINARY SCIENCES.

26.  Su YC, Burnouf PA, Chuang KH, Chen BM, Cheng TL*, Roffler SR*.Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy. Nat Commun. 2017 Jun 8;8:15507. 2020 SCIIF=14.919(SCI, 4/73=5.4%)in MULTIDISCIPLINARY SCIENCES.

27.  Lin WW, Cheng YA, Kao CH, Roffler SR, Lee YC, Chen BM, Hsieh YC, Chen IJ, Huang BC, Wang YT, Tung YC, Huang MY, Chen FM, Cheng TL*. Enhancement Effect of a Variable Topology of a Membrane-Tethered Anti-Poly(ethylene glycol) Antibody on the Sensitivity for Quantifying PEG and PEGylated Molecules. Anal Chem. 2017 Jun 6;89(11):6082-6090. 2020 SCI IF=6.986 (SCI, 8/83=9.6%) in CHEMISTRY, ANALYTICAL.

28.  Cheng KW, Tseng CH, Yang CN, Tzeng CC, Cheng TC, Leu YL, Chuang YC, Wang JY, Lu YC, Chen YL*, Cheng TL*.Specific Inhibition of Bacterial β-Glucuronidase by Pyrazolo[4,3-c]quinoline Derivatives via a pH-Dependent Manner To Suppress Chemotherapy-Induced Intestinal Toxicity. J Med Chem. 2017 Nov 22;60(22):9222-9238. 2020 SCI IF=7.446 (SCI, 3/63=4.7%) in CHEMISTRY, MEDICINAL.

29.  Chuang, CH; Wu, PC; Tsai, TH; Fang, YP; Tsai, YH; Cheng, TC; Huang, CC; Huang, MY; Chen, FM; Hsieh, YC; Lin, WW; Tsai, MJ*; Cheng, TL*. Development of pH-Sensitive Cationic PEGylated Solid Lipid Nanoparticles for Selective Cancer-Targeted Therapy. J Biomed Nanotechnol. 2017, Volume 13, Number 2, February pp. 192-203(12). 2020 SCI IF=4.099 (SCI, 19/40=47.5%)in MATERIALS SCIENCE, BIOMATERIALS.

30.  Tsai CH, Hsieh PW, Lee YC, Wang CH, Chiu WC, Lu CW, Wang YY, Hu SC, Cheng TL, Yuan SF3'-Hydroxy-4'-methoxy-β-methyl-β-nitrostyrene inhibits tumor growth through ROS generation and GSH depletion in lung cancer cells. Life Sci. 2017 Mar 1;172:19-26. 2020 SCI IF=5.037 (46/140=32.8%)in MEDICINE, RESEARCH & EXPERIMENTAL

31.  Ma CJ, Huang CW, Yeh YS, Tsai HL, Hu HM, Wu IC, Cheng TL, Wang JY;  Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer. Oncol Res. 2017 May 24;25(5):673-679.2020 SCI  IF=5.574 (SCI, 76/242=31.4%)in ONCOLOGY.

32.  Chang YT, Yeh YS, Ma CJ, Huang CW, Tsai HL, Huang MY, Cheng TL, Wang JY. Optimization of a multigene biochip for detection of relapsed and early relapsed colorectal cancer. J Surg Res. 2017 Dec;220:427-437.2020 SCI IF=2.192 (SCI, 121/212=57%) in SURGERY.

33.  Wang YT, Cheng TL*. Refined models of New Delhi metallo-beta-lactamase-1 with inhibitors: an QM/MM modeling study. J Biomol Struct Dyn. 2016 Oct;34(10):2214-23.2020 SCI IF=3.310 (23/73=31.5%) in BIOPHYSICS.

34.  Chang YT, Huang MY, Yeh YS, Huang CW, Tsai HL, Cheng TL, Wang JY.A Prospective Study of Comparing Multi-Gene Biomarker Chip and Serum Carcinoembryonic Antigen in the Postoperative Surveillance for Patients with Stage I-III Colorectal Cancer. PLoS One. 2016 Oct 4;11(10):e0163264. 2020 SCI IF=3.240 (SCI, 26/73=35.6%) in MULTIDISCIPLINARY SCIENCES.

35.  Lin WW, Hsieh YC, Cheng YA, Chuang KH, Huang CC, Chuang CH, Chen IJ, Cheng KW, Lu YC, Cheng TC, Wang YT, Roffler SR*, Cheng TL*.Optimization of an Anti-poly(ethylene glycol) (anti-PEG) Cell-Based Capture System To Quantify PEG and PEGylated Molecules. Anal Chem. 2016 Dec 20;88(24):12371-12379.2020 SCI IF=6.986 (SCI, 8/83=9.6%) in CHEMISTRY, ANALYTICAL.

36.  Hsieh YC, Cheng TC, Wang HE, Li JJ, Lin WW, Huang CC, Chuang CH, Wang YT, Wang JY, Roffler SR, Chuang KH, Cheng TL*. Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles. Sci Rep. 2016 Dec 19;6:39119. doi: 10.1038/srep39119.2020 SCIIF=4.379 (SCI, 17/73=23.2%) in MULTIDISCIPLINARY SCIENCES.

37.  Hsieh YJ, Tseng SP, Kuo YH, Cheng TL, Chiang CY, Tzeng YM, Tsai WC. Ovatodiolide of Anisomeles indica Exerts the Anticancer Potential on Pancreatic Cancer Cell Lines through STAT3 and NF-κB Regulation. Evid Based Complement Alternat Med. 2016;2016:8680372. 2020 SCI IF=2.629 (SCI, 12/29=41.3%) in INTEGRATIVE & COMPLEMENTARY MEDICINE.

38.  Chen BM, Su YC, Chang CJ, Burnouf PA, Chuang KH, Chen CH, Cheng TL, Chen YT, Wu JY, Roffler SR. Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals. Anal Chem. 2016 Nov 1;88(21):10661-10666. 2020 SCI IF=6.986 (SCI, 8/83=9.6%) in CHEMISTRY, ANALYTICAL.

39.  Lin WW, Chen IJ, Cheng TC, Tung YC, Chu PY, Chuang CH, Hsieh YC, Huang CC, Wang YT, Kao CH, Roffler SR, Cheng TL*.A Secondary Antibody-Detecting Molecular Weight Marker with Mouse and Rabbit IgG Fc Linear Epitopes for Western Blot Analysis. PLoS One. 2016 Aug 5;11(8):e0160418. 2020 SCI IF=3.240 (SCI, 26/73=35.6%) in MULTIDISCIPLINARY SCIENCES

40.  Huang WC, Burnouf PA, Su YC, Chen BM, Chuang KH, Lee CW, Wei PK,Cheng TL*, Roffler SR*.Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells. ACS Nano. 2016 Jan 26;10(1):648-62.2020 SCI IF=15.881 (SCI, 11/107=10.2%) in NANOSCIENCE & NANOTECHNOLOGY.

41.  Prijovich ZM, Burnouf PA, Chou HC, Huang PT, Chen KC,Cheng TL, Leu YL, Roffler SR.Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation. Mol Pharm. 2016 Apr 4;13(4):1242-50.2020 SCI IF= 4.939 (SCI, 68/275=24.7%) in PHARMACOLOGY & PHARMACY.